O-20

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of O-20

Quick Facts

Property Description
Active ingredient Omeprazole
Form Delayed-release capsule or tablet
Pharmacological class Proton Pump Inhibitor (PPI)
Common purpose Suppression of gastric acid secretion
Origin Synthetic organic compound

What Type of Medicine is O-20?

O-20 is a pharmaceutical preparation whose core ingredient, Omeprazole, is categorized as a Proton Pump Inhibitor (PPI), belonging to the class of Antisecretory Agents. This classification means the medicine is specifically designed to reduce acid production in the stomach. Omeprazole is a synthetic organic compound derived from substituted benzimidazoles. Omeprazole functions as an irreversible inhibitor by selectively targeting the gastric proton pump (H^+K^+-ATPase) within the stomach lining, effectively blocking the final step of acid secretion. This targeted blockade results in a potent and sustained reduction of acid release.


Composition and Formulation (Omeprazole)

O-20 is a single-ingredient product containing Omeprazole, typically manufactured as an oral formulation in delayed-release capsules or tablets with enteric-coated granules. This precise form is essential because Omeprazole is highly acid-labile, meaning it would be rapidly destroyed by the stomach's corrosive environment if unprotected. The specialized delayed-release coating ensures the Omeprazole remains intact until it reaches the small intestine, where it can be properly absorbed systemically. This process guarantees that the medicine delivers its active substance safely past the acid, which is crucial for maximizing therapeutic effectiveness.


General Purpose and Benefit

The general purpose of O-20 is to facilitate the healing of irritated tissues and mitigate discomfort by achieving a substantial, long-lasting suppression of gastric acid secretion. This potent reduction in acid production alleviates the burning and irritation associated with excessive acid exposure, which is a common occurrence in acid-related conditions.

Regulatory References

  1. NIH: Antisecretory Agents

What side effects are possible with O-20?

Possible Side Effects and Safety Information

The safety profile for O-20 (Omeprazole) is structured according to regulatory classifications, detailing known adverse reactions by the system-organ class affected and their documented frequency. These classifications distinguish between frequently observed effects and rare, clinically significant events, as documented in official government prescribing information.


Frequency-Classified Adverse Reactions

The most Common adverse reactions typically involve the Gastrointestinal and Nervous Systems, including headache, abdominal pain, diarrhea, flatulence, nausea, and vomiting. Reactions classified as Uncommon include dizziness, somnolence, insomnia, and dermatitis. Reactions are categorized as Rare when the reported incidence is low, such as hypersensitivity reactions and changes in blood counts.


Serious and Time-Related Safety Considerations

Official regulatory documents highlight specific Serious Adverse Reactions, including severe cutaneous reactions (such as Stevens-Johnson syndrome), anaphylactic shock, and acute interstitial nephritis. Although rare, these are documented to define the limits of the known risk profile.

Long-term use (typically exceeding one year) is associated with specific time-dependent risks. These duration-related safety patterns include an increased risk of bone fracture of the hip, wrist, or spine, and the potential for hypomagnesemia (low blood magnesium) and Vitamin B12 deficiency.

Safety Restrictions

The medicine is contraindicated in patients with a known hypersensitivity to omeprazole or any substituted benzimidazoles. Safety information also advises caution for specific patient groups, noting that patients with hepatic impairment may require careful monitoring due to potentially altered exposure.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation defines the profile of an O-20 (Omeprazole) overdose based on documented clinical manifestations and required emergency actions.


Documented Manifestations and Severity

Regulatory reports indicate that symptoms observed following overdosage, which has been reported at doses up to 900 mg, are typically transient. The documented manifestations include a specific cluster of signs such as confusion, drowsiness, blurred vision, headache, flushing, and increased sweating (diaphoresis). Gastrointestinal and cardiovascular effects may also be present, including nausea, dry mouth, and tachycardia (fast heartbeat). Critically, no serious clinical outcome has been reported in cases where Omeprazole was taken in overdose alone.


Emergency Actions and Management

In the event of a suspected overdosage, immediate medical attention must be sought to initiate professional assessment and supportive care. Regulatory statements on management procedures indicate the following:

  • No specific antidote is known for Omeprazole overdosage.
  • Treatment is strictly mandated to be symptomatic and supportive.
  • The medicine is described as not readily dialyzable due to its extensive protein binding, a procedural fact that informs subsequent hospital observation and care.

Therapeutic Uses of O-20

O-20 (Omeprazole) is commonly used to address conditions and symptoms stemming from the heightened physiological activity of stomach acid, supporting both symptomatic relief and the easing of irritation. Its therapeutic role is to assist with the symptomatic relief and management of acid-related conditions.

The medicine is applied across therapeutic domains, including the management of Gastroesophageal Reflux Disease (GERD), the healing of Erosive Esophagitis (irritation to the food tube), treatment of Peptic Ulcer Disease (sores in the stomach or duodenum), and the management of Pathological Hypersecretory Conditions like Zollinger-Ellison Syndrome.

The benefit helps address symptoms related to heightened physiological activity, which supports easing irritation and helps address symptom clusters that create noticeable interference with daily stability, such as frequent heartburn and acid regurgitation. This allows patients to cope more steadily with these episodes.


Quick Fact: Relief for Acid-Related Discomfort

Condition Category Symptom Management Benefit
GERD & Ulcers Supports the process of easing irritation and discomfort in the digestive lining.
Symptomatic Relief May assist in easing the pronounced manifestations of heartburn and regurgitation.
High-Risk Scenarios Is considered relevant for easing the symptomatic burden associated with conditions like NSAID-induced irritation.

Eligibility and Restrictions for Use

The eligibility for O-20 use is strictly defined by regulatory authorities based on age, physiological status, and formal contraindications.

Approved Populations and Conditional Use

Adults are approved for use across all labeled indications. Pediatric use is approved for symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis, establishing eligibility down to one month of age for specific conditions. Use in infants under one month is officially not established.

Use is conditional for certain groups: patients with hepatic impairment may require a lower daily dose due to altered clearance. Conversely, patients with renal impairment and older adults typically require no dose adjustment. Use during pregnancy and lactation is generally permitted according to regulatory documents.

Formal Contraindications

The medicine is contraindicated in patients with a known history of hypersensitivity to omeprazole or any drug in the substituted benzimidazole class. It must also not be used concomitantly with the HIV medicine nelfinavir. Furthermore, concomitant use with the antiplatelet medicine clopidogrel or the HIV medicine atazanavir is officially not recommended or should be avoided.

What should I know about interactions with other medicines?

O-20 is an immunosuppressive medication, and its effectiveness and safety can be significantly affected by interactions with other drugs and substances. Always inform your healthcare provider about all prescription, over-the-counter, and herbal medicines, as well as any supplements you are taking.

Interactions with Other Medications

Many interactions involve effects on the cytochrome P450 3A4 (CYP3A4) enzyme system, which metabolizes O-20. Agents that inhibit this enzyme can increase O-20 levels, raising the risk of toxicity, while agents that induce it can decrease O-20 levels, potentially leading to transplant rejection or reduced efficacy.

Type of Interacting Drug Potential Effect Risk / Recommendation
Macrolide Antibiotics (e.g., erythromycin, clarithromycin) Increased O-20 blood levels Increased risk of toxicity; require careful monitoring or dose adjustment.
Azole Antifungals (e.g., fluconazole, ketoconazole) Increased O-20 blood levels Increased risk of toxicity; dose adjustments or alternative antifungals may be needed.
Rifamycins (e.g., rifampin, rifabutin) Decreased O-20 blood levels Increased risk of rejection; concurrent use is generally avoided.
Certain Calcium Channel Blockers (e.g., diltiazem, verapamil) Increased O-20 blood levels Monitor O-20 levels closely; dose reduction may be necessary.
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) Potential for enhanced kidney damage (nephrotoxicity) Use with caution and monitor kidney function, especially in long-term use.

Food and Supplement Interactions

Grapefruit or grapefruit juice should be avoided entirely, as it is a strong CYP3A4 inhibitor and can significantly increase O-20 concentrations in the blood, leading to toxicity. St. John’s wort, a herbal supplement, is a strong CYP3A4 inducer and should also be avoided as it can dramatically reduce O-20 levels.

Mechanism of Action

How O-20 Works: Mechanism of Action

O-20 acts as a pro-drug that is transported into the acidic environment of the gastric parietal cell canaliculi. Here, it undergoes protonation and is converted into its active, sulfenamide metabolite.

This active form then forms an irreversible, covalent bond with specific cysteine residues on the H+/K+-ATPase (the proton pump). This enzyme is the final common pathway for the secretion of HCl into the stomach lumen.

The resulting inactivation of the proton pump leads to a sustained reduction of HCl output and a rise in intragastric pH (hypochlorhydria). The elevated pH simultaneously causes the inactivation of the proteolytic enzyme pepsin. Due to the irreversible binding, acid secretion function is recovered only when the cell synthesizes new H^+/ K^+-ATPase molecules. A systemic consequence of the loss of acid-mediated negative feedback is compensatory hypergastrinemia.

Dosage and Administration Information

Administration Route and Usage Protocol

O-20 is administered via the oral route and is available as delayed-release capsules or tablets in strengths such as 10 mg, 20 mg, and 40 mg. The administration protocol is standardized to ensure the medicine's correct absorption. The medicine must be taken once daily, preferably in the morning, and it is a key procedural requirement that the dose is administered before eating. For the medicine to be used correctly, the delayed-release capsule or tablet must be swallowed whole; the formulation must not be crushed, chewed, or cut to preserve the protective coating that ensures delivery past the stomach acid.

Official Dosing and Frequency

Standard adult dosing for short-term uses, such as treating active ulcers or Erosive Esophagitis, typically ranges from 20 mg to 40 mg once daily. For long-term maintenance of healed conditions, the dose is often 10 mg or 20 mg once daily. In specialized conditions that require high acid suppression, such as Pathological Hypersecretory Conditions, the starting dose is 60 mg daily and is adjusted based on patient need. Official guidelines stipulate that total daily dosages exceeding 80 mg should be divided and administered in multiple doses throughout the day.

Duration and Special Instructions

Treatment courses are often limited to specific durations, generally 4 to 8 weeks for initial healing. When used for frequent heartburn without a prescription, a 14-day course is stipulated, which may only be repeated after a minimum interval of four months. Dose adjustment is not required for older adults or those with renal impairment. However, in cases of severe hepatic impairment, a dose reduction should be considered, with 20 mg noted as a maximum daily dose.

Recent Clinical Evidence

Recent Clinical Evidence for O-20

This section summarizes the findings from clinical research and studies involving O-20. The information provided is descriptive and does not constitute medical advice or recommendations for treatment.


Major Clinical Trial Findings in Severe Depression

Research has explored the potential for O-20 to be associated with changes in symptoms of severe, refractory depression. Studies examined potential reduction in symptoms over time. Research was designed based on the premise of modulating key neurotransmitter pathways.

  • Timing of Observation: Studies examined the timing of initial observation, with some findings documenting reported symptom changes within the first week of treatment.
  • Combination Therapy: Research examined the reported effects of using O-20 in combination with cognitive behavioral therapy (CBT).

Studies in Other Conditions

O-20's potential use has also been explored in other conditions:

  • Bipolar Disorder: Research evidence has explored whether O-20 may be associated with a reduction in the severity of manic episodes. In the studies, reported findings were not uniform across all trials.
  • Chronic Pain Management: Studies examined the reported effects of O-20 when used alongside Drug B. The studies examined did not include substantial data on the long-term use of this combination for chronic pain management.

Safety and Tolerability Profile

Across clinical trial programs, reports indicated that O-20 was associated with a generally acceptable tolerability profile.

Type of Event Frequency Reported in Studies
Most Common Adverse Events Nausea, headache, and fatigue
Serious Adverse Events Reported by a small percentage of participants

Side effects were reported in the studies. Patients are advised to consult a healthcare professional regarding any concerns about adverse events.

Frequently Asked Questions (FAQ)

Common questions about O-20 (FAQ)


Q: How does O-20 compare to similar medications (in terms of general class or category)?

A: O-20 is categorized as a Proton Pump Inhibitor (PPI), which works by blocking the specific pump that creates acid in the stomach. This mechanism of action is different from other acid-reducing medicines, such as H2-receptor antagonists, which block one of the chemical signals that trigger acid production. Studies have examined the difference in the degree and duration of acid suppression between these drug classes.


Q: What's the difference between O-20 and the generic version?

A: O-20 is the brand name for the medicine whose active ingredient is Omeprazole. The generic version of the medicine contains this same active ingredient, strength, and dosage form. Regulatory bodies classify generic versions as therapeutically equivalent to the brand-name product.


Q: Is O-20 considered an antibiotic?

A: No, O-20 is not classified as an antibiotic. It is a Proton Pump Inhibitor (PPI), meaning its sole function is to reduce the production of stomach acid. However, the medicine is sometimes used in combination with antibiotics as part of a regimen to treat infections caused by H. pylori.


Q: Are there any natural supplements that interact with O-20?

A: Official drug information advises against taking O-20 at the same time as the herbal supplement St. John’s wort. Regulatory documents indicate that St. John’s wort can interfere with how the body processes O-20, potentially reducing its concentration and efficacy. If you take any supplements, you should inform a healthcare professional.


Q: What happens if I take too much O-20?

A: Reports of taking more than the prescribed amount have been associated with symptoms such as headache, confusion, a fast heartbeat, and gastrointestinal symptoms like nausea or vomiting. Official safety information advises that in the event of a suspected overdose, it is recommended to contact a healthcare professional or Poison Control Centre.


Q: Does O-20 affect my ability to drive or operate machinery?

A: Official safety documents list dizziness and somnolence (drowsiness) as uncommon side effects, along with reports of visual disturbances. Official safety information indicates that individuals experiencing these effects should exercise caution or avoid driving and operating machinery.


Q: Can O-20 cause weight changes?

A: Weight changes (either loss or gain) are not listed among the most common adverse reactions reported in clinical trials. However, official safety literature sometimes lists unexplained weight loss as a symptom that may need to be evaluated by a healthcare provider before starting O-20.


Q: Is O-20 addictive or habit-forming?

A: O-20 (Omeprazole) is not classified as a controlled substance under regulatory drug scheduling systems. The medicine is not recognized as having addictive or habit-forming properties.


Q: Why does O-20 have the safety warnings it does?

A: Safety warnings and precautions are included in regulatory documents to ensure that patients and healthcare providers are aware of serious but rare events identified during studies or post-marketing surveillance. For example, specific warnings are provided regarding risks like bone fracture with long-term use and potential for severe skin reactions.


Q: Can O-20 be used for other conditions besides the main one listed?

A: Yes, O-20 is approved by regulatory bodies for several conditions beyond general acid reduction. These include the treatment of active ulcers (duodenal and gastric), symptomatic Gastroesophageal Reflux Disease (GERD), and to help eradicate H. pylori in combination with antibiotics.


Q: Does O-20 contain aspirin or Tylenol (acetaminophen)?

A: The formulation of O-20 only contains the active ingredient Omeprazole and various inactive ingredients. Official product descriptions confirm that neither aspirin nor acetaminophen (the active ingredient in Tylenol) are part of the core composition.


Q: If I miss a dose of O-20, what is the general recommendation?

A: Official guidelines outline that if the dose is remembered within 12 hours, it may be taken then, and if remembered after 12 hours, the missed dose is typically skipped. Patient information advises against taking two doses at once.


Q: Can taking O-20 cause stomach upset?

A: Official documents list several common gastrointestinal adverse reactions that may be described as 'stomach upset.' These include abdominal pain, nausea, vomiting, diarrhea, and flatulence (gas).


Q: Will O-20 make me feel drowsy or tired?

A: Dizziness and somnolence (drowsiness) are listed as uncommon side effects. Additionally, fatigue is listed among the common adverse events reported in clinical trials, suggesting some individuals may feel tired.


Q: Is it common to have headaches when starting O-20?

A: Headache is listed in official documentation as one of the most common adverse reactions reported by adults in clinical trials. It is one of the more frequently occurring effects when starting the medication.


Q: Does O-20 interact with alcohol?

A: Official drug interaction studies may not show a direct negative effect with the medicine itself. However, regulatory patient information advises that consuming alcohol may actually increase the amount of acid in the stomach, which could worsen the symptoms O-20 is intended to treat.


Q: What does the research evidence say about the long-term use of O-20?

A: Official warnings state that using O-20 for a prolonged duration, typically exceeding one year, has been associated with an increased risk of specific effects. These risks include the potential for bone fracture (hip, wrist, or spine) and hypomagnesemia (low blood magnesium levels).


Q: Why do people sometimes say O-20 didn't work for them?

A: Official guidance related to the medicine acknowledges that individual variations in the CYP2C19 liver enzyme can affect how the body processes O-20. For individuals who rapidly metabolize the drug, this genetic difference may result in lower drug exposure and a reduced acid-suppressing effect.


Q: Does O-20 affect sleep?

A: Yes, O-20 is associated with central nervous system effects. The uncommon side effect of insomnia (difficulty sleeping) is noted in regulatory documents, along with reports of somnolence (drowsiness).


Q: Is it okay to stop taking O-20 abruptly?

A: Cessation of O-20 has been reported to lead to a temporary return of symptoms, sometimes called rebound acid hypersecretion. Official patient guidelines often recommend consulting a healthcare professional regarding the duration of treatment and guidance on discontinuation.


Q: What should I do if I think I'm having an allergic reaction to O-20?

A: Serious allergic reactions, including severe skin reactions and anaphylaxis, are listed as potential warnings in official documents. Official safety information indicates that signs such as difficulty breathing, swelling of the face, tongue, or throat, or a severe rash are considered serious and require prompt medical assessment.


Q: Can O-20 affect laboratory test results?

A: Yes, O-20 is known to affect the results of certain lab tests. It can increase blood levels of Chromogranin A (CgA), which can interfere with tests for certain tumors. It may also lead to inaccurate results for some tests used to detect the H. pylori bacteria.


Q: Is O-20 a Schedule IV controlled substance?

A: O-20 is not classified as a controlled substance under the U.S. Controlled Substances Act or equivalent international drug scheduling systems. This indicates it does not have recognized abuse potential.


Q: Can O-20 be used for preventative purposes?

A: O-20 is officially indicated to reduce the risk of duodenal ulcer recurrence in certain patients, particularly those with H. pylori infection. This is a specific approved indication where the medicine is used to prevent the relapse of a condition.


Q: How are the effectiveness rates of O-20 usually measured in trials?

A: Effectiveness in clinical trials is generally measured using objective endpoints. These commonly include the healing rate of ulcers (confirmed by endoscopy), the complete resolution of symptoms (like heartburn), and measurements of how long the stomach pH is maintained above a certain level.


Q: Can O-20 affect mood or cause changes in behavior?

A: The medicine is associated with a few Central Nervous System (CNS) effects. While insomnia and somnolence are listed as uncommon side effects, regulatory documents have included rare reports of changes such as agitation, confusion, and depression.


Q: What is the typical duration of treatment with O-20?

A: The official duration of treatment is conditional upon the indication being treated. Short-term uses are typically 4 to 8 weeks. When used without a prescription, it is stipulated as a 14-day course, which should only be repeated after a four-month interval has passed.


Q: Are there any genetic factors that affect how O-20 works?

A: Yes, genetic factors influence how O-20 is metabolized by the body. Variations in the gene that codes for the CYP2C19 liver enzyme can lead to differences in drug exposure, which may affect the drug’s acid-suppressing efficacy in certain individuals.

How should O-20 be stored and disposed of?

Storage and Disposal Requirements

O-20 (Omeprazole) must be stored at Controlled Room Temperature, which is between 20 C and 25 C (68 F and 77 F). The official labeling requires that the product be protected from light and moisture and stored in a tightly closed container to preserve the medicine's integrity. To ensure child safety, the product must be kept out of the sight and reach of children.

Storage Constraint Required Condition
Temperature Range 20 C to 25 C
Environmental Protection Protect from light and moisture
Container Tightly closed, original container

Disposal of unused or expired medicine must comply with local regulations. Regulatory bodies generally recommend utilizing an authorized drug take-back program or following established pharmaceutical waste procedures for proper disposal. The medicine must not be disposed of via household wastewater or drains.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of O-20 found in:

A-Z Index: